Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update

The American Society of Clinical Oncology (ASCO) has published an updated clinical practice guideline on immunotherapy and targeted therapy in advanced gastroesophageal cancer in the Journal of Clinical Oncology (April 2026). The update consolidates evidence from registrational trials and restates the recommended treatment sequences, biomarker-driven agent selection and combination regimens for patients with unresectable or metastatic disease; it covers first-line and subsequent-line settings, including checkpoint inhibitor combinations and HER2-directed therapies. ASCO guidelines serve as a reference document for the oncology community — how they apply to an individual patient is a decision for the treating physician.